Ensign Peak Advisors, Inc Nurix Therapeutics, Inc. Transaction History
Ensign Peak Advisors, Inc
- $51.2 Billion
- Q1 2025
A detailed history of Ensign Peak Advisors, Inc transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 230,828 shares of NRIX stock, worth $2.89 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
230,828
Previous 374,673
38.39%
Holding current value
$2.89 Million
Previous $7.06 Million
61.15%
% of portfolio
0.01%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding NRIX
# of Institutions
181Shares Held
74.4MCall Options Held
56.9KPut Options Held
7.9K-
Black Rock Inc. New York, NY6.82MShares$85.3 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.5MShares$68.8 Million2.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$55.2 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.05MShares$50.6 Million5.06% of portfolio
-
Commodore Capital LP New York, NY3.98MShares$49.7 Million4.63% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $589M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...